CHAPTER INTRODUCTION... 1 CHAPTER REVIEW OF LITERATURE...

Σχετικά έγγραφα
Abstract... I. Zusammenfassung... II. 1 Aim of the work Introduction Short overview of Chinese hamster ovary cell lines...

Acknowledgements... 3 Contents... I Figures... VII Tables... IX Abbreviations... X

Cellular Physiology and Biochemistry

Τα ηπατικά επίπεδα του FOXP3 mrna στη χρόνια ηπατίτιδα Β εξαρτώνται από την έκφραση των οδών Fas/FasL και PD-1/PD-L1

Christopher Stephen Inchley, 2015

NOVEL INTEGRAL MEMBRANE PROTEINS OF THE INNER NUCLEAR MEMBRANE

Chapter 1. Fingolimod attenuates ceramide induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes

P450 CYP4G19. Prokaryotic Expression of German cockroach Cytochrome P450 CYP4G19 Gene and Preparation of Polyclonal Antibody , ; 2.

Group 2 Methotrexate 7.5 mg/week, increased to 15 mg/week after 4 weeks. Methotrexate 7.5 mg/week, increased to 15 mg/week after 4 weeks

TABLE OF CONTENTS Page

Shiraia sp. Slf14 III

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΑΝΟΙΚΤΑ ΑΚΑΔΗΜΑΪΚΑ ΜΑΘΗΜΑΤΑ

Contents Part I Psychoneuroimmunology and Systems Biology Mechanisms 1 From Psychoneuroimmunology to Personalized, Systems, and Dynamical Medicine

α α Pneumocystis jirovecii

Πρόσκληση υποβολής προσφοράς

Structural and Biochemical Studies of Cotranslational Protein Transport across the Endoplasmic Reticulum

Chapter 1 Introduction to Observational Studies Part 2 Cross-Sectional Selection Bias Adjustment

Abstract -12, V NSC B

BD Cytometric Bead Array Flex Set System

Table of contents. 1. Introduction... 4

Monday 26 January2015

Ara h 2. pet - 32a + Origami. Western blotting ELISA SDS - PAGE Ara h 2 F - Ara h 2. IgE

ΜΟΡΙΑΚΕΣ ΜΕΘΟΔΟΙ ΚΡΙΤΗΡΙΑ ΕΠΙΛΟΓΗΣ ΑΞΙΟΛΟΓΗΣΗ

< (0.999) Graft (0.698) (0.483) <0.001 (0.698) (<0.001) (<0.001) 3 months (0.999) (0.483) (<0.001) 6 months (<0.

Παθογένεια της ΧΑΠ: νεώτερα δεδοµένα. Καθηγητής: : N.M.Σιαφάκας Ιατρική Σχολή Πανεπιστήµιο Κρήτης

Characterization of the molecular networks that control pathogenic T-cell driven responses in Multiple Sclerosis using RNA-seq analysis software

JEV C RNA 11kb 3. Japanese encephalitis virus JEV JEV C 7. C E prm C 1 RNA. Gold pgbkt7 pgadt7- T pgbkt7-53 pgbkt7- JEV C PCR JEV C cdna

1., Specificity and Epitope Mapping of Four Monoclonal Antibodies. against SARS-CoV Nucleocapsid Protein

svari Real-time RT-PCR RSV

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΑΝΟΙΚΤΑ ΑΚΑΔΗΜΑΪΚΑ ΜΑΘΗΜΑΤΑ. Παθοφυσιολογία Ι

, SLC26A4 HEK 293. The construction of wild-type SLC26A4 gene expression vector and the expression in HEK293 cells

Speakers Index Ευρετήριο Ομιλητών

High mobility group 1 HMG1

α 1 2- Cloning and Expression of alpha 1 2-fucosyltransferase in E. coli BIOTECHNOLOGY BULLETIN

TABLE OF CONTENT. Chapter Content Page

A strategy for the identification of combinatorial bioactive compounds. contributing to the holistic effect of herbal medicines

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΓΕΩΤΕΧΝΙΚΩΝ ΕΠΙΣΤΗΜΩΝ ΚΑΙ ΔΙΑΧΕΙΡΙΣΗΣ ΠΕΡΙΒΑΛΛΟΝΤΟΣ. Πτυχιακή εργασία

MOTROL. COMMISSION OF MOTORIZATION AND ENERGETICS IN AGRICULTURE 2014, Vol. 16, No. 5,

Study on AgrobacteriunΟmediated transformation of tobacco plant with rol C gene

Χυμική Ανοσία. Γιάννης Ρούτσιας, MD, PhD Επικ καθηγητης Ανοσολογίας Μικροβιολογίας

Παιδιατρική ΒΟΡΕΙΟΥ ΕΛΛΑΔΟΣ, 23, 3. Γ Παιδιατρική Κλινική, Αριστοτέλειο Πανεπιστήμιο, Ιπποκράτειο Νοσοκομείο Θεσσαλονίκης, 2

15 1 Vol. 15 No Journal of Medical Postgraduates Feb (MIF) IgG IgM IgA PBMC. npcr (36. 5 % %, P < 0. 01) 84.

Introduction to Bioinformatics

Statistical analysis of extreme events in a nonstationary context via a Bayesian framework. Case study with peak-over-threshold data

ΠΡΟΣΚΛΗΣΗ ΕΚΔΗΛΩΣΗΣ ΕΝΔΙΑΦΕΡΟΝΤΟΣ

OPEN -- Overall Stage Results ΜΑΚΕΔΟΝΙΚΟ ΚΥΠΕΛΛΟ Printed Οκτώβριος 30, 2012 at 18:15

ΟΔΗΓΟΣ ΓΙΑ ΤΗΝ ΑΠΟΣΤΟΛΗ ΔΕΙΓΜΑΤΩΝ SEQUENCING. Sample Requirements

A/A Είδος Προδιαγραφές

,Ab 2 Ab 1. (internal image) Ab 2 : (1) Ab 1,


encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ BIOCHEMICAL JOURNAL

Table S1: Inpatient Diet Composition

ΕΠΙΔΡΑΣΗ ΤΗΣ ΧΡΗΣΗΣ ΕΛΑΙΟΠΛΑΚΟΥΝΤΑ ΣΤΗΝ ΔΙΑΤΡΟΦΗ ΤΩΝ ΑΙΓΩΝ ΔΑΜΑΣΚΟΥ ΩΣ ΠΡΟΣ ΤΗΝ ΠΟΣΟΤΗΤΑ ΚΑΙ ΠΟΙΟΤΗΤΑ ΤΟΥ ΠΑΡΑΓΟΜΕΝΟΥ ΓΑΛΑΚΤΟΣ

Η κυριότερη μέθοδος τυποποίησης είναι η Αιμοσυγκόλληση. Αιμοσυγκόλληση είναι ο σχηματισμός συγκολλήσεων αθροισμάτων ερυθρών ύστερα από την ειδική

Research on Economics and Management

(Pseudorabies,PR) , ge. , ( Pichia pastoris) ppic9k, ,Multi2Copy Pichia Expression Kit Invitrogen, Vol. 42 October No. 5

Μελέτη της επίδρασης αντικαρκινικών χημειοθεραπευτικών φαρμάκων στη ρύθμιση του Cdt1

ΜΙΑ ΟΛΙΣΤΙΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΤΗΝ ΠΟΙΟΤΗΤΑ ΤΟΥ ΓΑIΔΟΥΡΙΝΟΥ ΓΑΛΑΚΤΟΣ ΣΤΗΝ ΚΥΠΡΟ

ΠΟΛΥΤΕΧΝΕΙΟ ΚΡΗΤΗΣ ΤΜΗΜΑ ΜΗΧΑΝΙΚΩΝ ΠΕΡΙΒΑΛΛΟΝΤΟΣ

Chalkou I. C. [PROJECT] Ανάθεση εργασιών.

Synthesis and Biological Evaluation of Novel Acyclic and Cyclic Glyoxamide derivatives as Bacterial Quorum Sensing and Biofilm Inhibitors

genomics, proteomics, metabolomics ELISA Enzyme-Linked ImmunoSorbent Assay ECL Electrochemi-luminescence SPR Surface Plasmon Resonance ECL

Supplementary Table 1. Primers used for RT-qPCR analysis of striatal and nigral tissue.

Nucleotide Sequence of Cloned cd NA for alpha Subunit of Goat Follicle Stimulating Hormone

MALMÖ UNIVERSITY HEALTH AND SOCIETY DISSERTATION 2014:3 ANTON FAGERSTRÖM EFFECTS OF SURFACTANT ADJUVANTS ON PLANT LEAF CUTICLE BARRIER PROPERTIES

Studies on purification and characteristics of glycosyltransferase from an engineering strain

Το Βιολογικό Ρολόι: Θεµελιώδης Ρυθµιστής της Φυσιολογίας των Οργανισµών

Does anemia contribute to end-organ dysfunction in ICU patients Statistical Analysis

Η επιστήμη στην ιατρική εξαρτάται από την επικοινωνία. Να αναμεταδώσουμε Παρατηρήσεις μας Τα συμπεράσματα Την εξήγηση Και την πιθανή εξήγηση μας

Effects of Polygonatum sibiricum Polysaccharide on Immunosuppressive Action Induced by Cyclophosphamide in Mice

Τα ερευνητικά προγράμματα του ERC και η συμβολή τους στη στρατηγική ανάπτυξης ενός Οργανισμού Υποδοχής

Supplementary Materials: A Preliminary Link between Hydroxylated Metabolites of Polychlorinated Biphenyls and Free Thyroxin in Humans

THE GENETIC TRANSFORMATION OF STRAWBERRY WITH WINTER FLOUNDER ANTIFREEZE PROTEIN GENE

ΠΑΡΑΣΚΕΥΗ, 24 Οκτωβρίου Σεμινάριο: ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΑΓΚΡΕΑΤΟΣ

Mηχανισμοί Φλεγμονής στο Άσθμα. Μίνα Γκάγκα ΝΝΘΑ

Θεραπευτική. Θεραπευτικές προτάσεις στην Πέμφιγα. Treatment Approaches in Pemphigus. Ðå ñß ëç øç. Summa ry

Salmonella produce microrna-like RNA fragment Sal-1 in the infected cells to. facilitate intracellular survival


Mitomycin C application for the prevention of postoperative synechiae formation at the anterior commissure.

Ίδρυμα Τεχνολογίας & Έρευνας (ΙΤΕ)

Ραδιοσηµασµένοι προσδέτες για την C5aR-στοχευµένη. απεικονιστική διάγνωση λοιµώξεων. Πρόγραµµα ΗΜΟΕΡΕΥΝΑ-2006

In silico modeling studies of the immune modulatory mechanisms in Inflammatory Bowel Disease

þÿ Ç»¹º ³µÃ ± : Ãż²» Ä Â

Μελέτη των μεταβολών των χρήσεων γης στο Ζαγόρι Ιωαννίνων 0

Intestinal protozoal infection, Traveller's diarrhoea, Giardia lamblia

Malgorzata Korycka-Machala, Marcin Nowosielski, Aneta Kuron, Sebastian Rykowski, Agnieszka Olejniczak, Marcin Hoffmann and Jaroslaw Dziadek

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΚΥΠΡΟΥ ΤΜΗΜΑ ΝΟΣΗΛΕΥΤΙΚΗΣ. Πτυχιακή Εργασία

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ ΙΑΤΡΙΚΗ ΣΧΟΛΗ. ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥ ΩΝ «Ιατρική Ερευνητική Μεθοδολογία» ΙΠΛΩΜΑΤΙΚΗ ΕΡΓΑΣΙΑ

glutamine arginine (Field, Johnson, and Pratt, 2000) human immunodeficiency virus HIV

Analysis of hydrophilic components in water. extract from Polygonum multiflorum using. micellar electrokinetic chromatography

.(c.s.f ) (Sylvius) (Magendie

Calcitonin Gene-Related Peptide and Migraine:

Supplementary Materials for Evolutionary Multiobjective Optimization Based Multimodal Optimization: Fitness Landscape Approximation and Peak Detection

Η ΦΛΕΓΜΟΝΩ ΗΣ ΑΝΤΙ ΡΑΣΗ ΤΟΥ ΓΑΣΤΡΙΚΟΥ ΒΛΕΝΝΟΓΟΝΟΥ ΣΤΗ ΛΟΙΜΩΞΗ ΜΕ ΕΛΙΚΟΒΑΚΤΗΡΙ ΙΟ ΤΟΥ ΠΥΛΩΡΟΥ ΠΡΙΝ ΚΑΙ ΜΕΤΑ ΤΗ ΘΕΡΑΠΕΙΑ

PRESENTATION TITLE PRESENTATION SUBTITLE

Expression and Purification of HIV-1 Protease and the Establishment. of a Method for Protease Inhibitor Screening

ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ ΤΕΧΝΟΛΟΓΙΚΟ ΕΚΠΑΙΔΕΥΤΙΚΟ ΙΔΡΥΜΑ (Τ.Ε.Ι.) ΗΠΕΙΡΟΥ ΕΠΙΤΡΟΠΗ ΕΚΠΑΙΔΕΥΣΗΣ & ΕΡΕΥΝΩΝ ΓΡΑΜΜΑΤΕΙΑ ΕΙΔΙΚΟΥ ΛΟΓΑΡΙΑΣΜΟΥ

Άσκηση 10, σελ Για τη μεταβλητή x (άτυπος όγκος) έχουμε: x censored_x 1 F 3 F 3 F 4 F 10 F 13 F 13 F 16 F 16 F 24 F 26 F 27 F 28 F

Ανοσογονικότητα βιολογικών παραγόντων. Νικόλαος Ζερβός Ρευματολόγος 251 ΓΝΑ

ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥΔΩΝ ΣΤΙΣ «ΚΛΙΝΙΚΕΣ ΚΑΙ ΚΛΙΝΙΚΟΕΡΓΑΣΤΗΡΙΑΚΕΣ ΙΑΤΡΙΚΕΣ ΕΙΔΙΚΟΤΗΤΕΣ»

Transcript:

Table of Content CHAPTER-1... 1 1 INTRODUCTION... 1 CHAPTER-2... 4 2 REVIEW OF LITERATURE... 4 2.1 History of Filariasis... 4 2.1.1 Discovery of Symptoms (1588-1592)... 4 2.1.2 Discovery of Microfilariae (1863 and 1866)... 4 2.1.3 Discovery of Adult Worm (1876)... 5 2.1.4 Discovery of Filarial Life Cycle (1877)... 5 2.1.5 Discovery of Transmission (1900)... 5 2.2 Causative agent... 7 I. Wuchereria bancrofti... 7 II. Brugia malayi... 7 III. Brugia timori... 8 2.3 Life cycle of B. malayi... 9 2.3.1 Development in intermediate host (mosquito)... 9 2.3.2 Development in definitive host (humans or rodents)... 9 2.3.3 Periodicity... 10 2.4 Epidemiology... 11 2.4.1 Global Distribution... 11 2.4.2 Current situation in India... 12 2.4.3 Economic burden of disease... 13 2.4.4 Disability adjusted Life years (DALY)... 14 2.4.5 Hold in endemic countries... 15 2.5 Symptoms and pathology... 15 2.6 Development of the disease... 16 2.6.1 The pre-patent period (biological incubation period)... 16 2.6.2 The patent (symptom-less) period... 16 2.6.3 The acute or allergic stage... 16 2.6.4 The chronic manifestations... 17 2.7 Categories of filarial subjects in filaria endemic area... 17 2.7.1 Mf carriers... 17 2.7.2 Symptomatic... 17 2.7.3 Endemic normal... 18 2.7.4 Other forms of filariasis... 19 2.8 Pathogenesis... 20 2.9 Disease management... 22 2.9.1 Diagnosis... 22

2.9.1.1 New advances in diagnosis... 23 2.9.2 Treatment and control... 26 2.9.3 Global Programme to Eliminate Lymphatic Filariasis (GPELF)... 29 2.10 Vector control... 31 2.11 Drug targets... 34 2.12 Newer targets from Brugia genome... 38 2.13 Vaccine development... 39 2.14 Vaccine targets... 40 2.15 Immune response against filarial infection... 41 2.15.1 Host-parasite interactions... 41 2.15.2 Humoral immune responses... 41 2.15.3 Cellular immune responses... 43 2.16 Molecular basis of immune responses... 43 2.17 Cells involved in inflammatory response... 46 2.18 Immune modulation: in vivo mechanisms... 50 2.19 Role of DIM-1 protein... 51 CHAPTER-3... 54 3 MATERIALS AND METHODS... 54 3.1 Animals... 54 3.2 Parasite... 54 3.3 Animal models... 54 3.4 Maintenance of B. malayi infection... 56 3.4.1 Rearing and breeding of A. aegypti colony... 56 3.4.2 Feeding of mosquitoes on mf positive M. coucha... 56 3.4.3 Isolation of L3 from mosquitoes... 57 3.4.4 Inoculation of L3 to M. coucha/jird and assessment of the infection... 58 3.5 Cloning... 60 3.5.1 Gene selection... 60 3.5.2 Design of primer for the gene... 60 3.5.3 mrna isolation... 61 3.5.3.1 Isolation of adult parasites... 61 3.5.3.2 mrna isolation by Trizol method... 61 3.5.4 cdna synthesis... 62 3.5.5 PCR amplification of gene... 66 3.5.5.1 Elution of amplified DNA (gene product) from the gel... 67 3.5.6 Cloning of DNA in TA vector... 67 3.5.6.1 Ligation of PCR product and TA vector... 68 3.5.6.2 Transformation in DH5α competent strain of E.coli... 69 3.5.6.3 Confirmation of positive colony by colony PCR... 70 3.5.6.4 Sequencing of gene... 70

3.5.7 Sub cloning of DIM-1 TA clone in expression vector (ptriex-4)... 71 3.5.7.1 Isolation of plasmid DNA from transformed E. coli... 71 3.5.7.2 Expression vector (ptriex-4)... 71 3.5.7.3 Restriction digestion of plasmid of TA clone and plasmid of expression vector (ptriex-4)... 72 3.5.7.4 Elution of digested plasmid from the gel... 73 3.5.7.5 Ligation of digested expression vector with amplified product... 73 3.5.7.6 Transformation... 74 3.5.7.7 Confirmation of clone... 74 3.5.7.8 Isolation of plasmid from transformed DH5α cells... 74 3.5.8 Over expression of DIM-1 in expression cell (BL21-DE3 cells)... 74 3.5.8.1 Transformation of isolated plasmid in BL21-DE3 cells... 74 3.5.8.2 Confirmation of clones by colony PCR... 74 3.5.8.3 Expression of proteins from transformed E. coli BL21-DE3 cells... 75 3.5.9 Checking of protein solubility... 75 3.5.10 Purification of recombinant DIM-1 of B. malayi (rdim-1bm) by Ni NTA-column (affinity chromatography)... 79 3.5.11 Protein estimation by Bradford method... 82 3.5.12 Western blotting for transfer of resolved proteins on nitro cellulose paper (NCP)...83 3.5.13 Confirmation of r-protein with anti-histidine antibody in western blot... 85 3.5.14 Bacterial endotoxins test for recombinant DIM-1... 85 3.6 Sequence and phylogenetic analysis... 87 3.7 In silico modeling studies... 87 3.8 Immuonolocalization of DIM-1 in B. malayi adult parasite by confocal microscopy... 88 3.9 Reactivity of antibodies to rdim-1bm with resolved fractions of mf, L3, L4 and adult worm stages by immunoblotting... 89 3.9.1 Isolation of parasites (adult and L4) and preparation of parasite extract... 89 3.9.2 Isolation of L3 and preparation of parasite extract... 90 3.9.3 Isolation of mf and preparation of mf extract... 90 3.9.4 Fractionation of different stages of B. malayi by SDS-PAGE... 90 3.9.5 Immunoblotting of resolved component of mf, L3, L4 and BmA with sera of rdim- 1bm immunized M. coucha...90 3.10 Immune responses of rdim-1bm immunized animals... 91 3.10.1 Grouping and immunization of animals... 91 3.10.1.1 Immunization and experimental schedule... 91 3.10.2 Assessment of infection status... 92 3.10.3 Weekly body weight... 94 3.10.4 Rectal temperature... 94 3.10.5 Hematology (at autopsy)... 94

3.10.5.1 Collection of Blood... 94 3.10.5.2 Total leukocyte count (TLC)... 95 3.10.5.3 Differential leukocyte count (DLC)... 95 3.10.5.4 Packed cell volume (PCV)... 95 3.10.5.5 Erythrocyte sedimentation rate (ESR)... 95 3.10.5.6 Haemoglobin concentration (Hb)... 95 3.10.6 Humoral mediated immune response... 96 3.10.6.1 Determination of IgG antibody and subtypes... 96 3.10.6.2 Determination of specific IgE... 96 3.10.6.3 Determination of specific IgM... 97 3.10.6.4 Determination of specific IgA... 97 3.10.7 Cell mediated immune response... 97 3.10.7.1 Nitric oxide production by macrophages... 97 3.10.7.2 Cellular proliferation (lymphocyte transformation test; LTT)... 99 3.10.7.3 Cytokine determination by ELISA... 99 3.10.7.4 Macrophage function test... 100 3.11 Histopathology of lymph nodes...100 3.12 Statistical analysis...101 CHAPTER-4... 102 4 RESULTS... 102 4.1 Cloning of DIM-1... 102 4.1.1 Amplification of DIM-1 gene... 102 4.1.2 Sub cloning of amplified product in ptz57r/t vector... 102 4.1.3 Sub cloning of gene in the expression vector (ptriex4)... 103 4.1.4 Over expression and purifiaction of rdim-1bm... 104 4.1.5 In silico DIM-1bm sequence analysis... 105 4.1.6 Molecular modeling studies... 108 4.1.7 Confocal microscopy to localize rdim-1bm in adult B. malayi... 109 4.1.8 Reactivity of rdim-1bm with resolved fractions of various stages of B. malayi... 110 4.2 NO release, cellular proliferation, proinflammatory (TNF -α, IFN- and IL-6) and antiinflammatory (IL-10) cytokine production in splenocytes of normal M. coucha stimulated with rdim-1bm... 111 4.2.1 Nitric oxide (NO) release... 111 4.2.2 Cellular proliferation response... 111 4.2.3 Cytokines release... 112 4.3 Effect of repeated exposures of M. coucha to rdim-1bm... 113 4.3.1 3-Dose immunization schedule (standard immunization protocol for vaccination) 113 4.3.1.1 In-life observations... 113 4.3.1.1.1 Behavior... 113 4.3.1.1.2 Body weight... 113

4.3.1.1.3 Rectal temperature... 114 4.3.1.1.4 Organ weight... 115 4.3.1.2 Hematological parameters... 115 4.3.1.3 Parasitological responses... 117 4.3.1.3.1 Effect of rdim-1bm on L3 induced infection... 117 4.3.1.4 Immunological responses... 118 4.3.1.4.1 Effect on humoral responses: IgG and its subclass, IgE, IgM and IgA......118 4.3.1.5 Effect on cell mediated immune responses... 119 4.3.1.5.1 Lymphocyte transformation test (LTT)... 119 4.3.1.5.2 Macrophage phagocytic activity test (MAT)... 120 4.3.1.5.3 NO release... 120 4.3.1.5.4 Cytokine release... 120 4.3.2 3- Week immunization schedule (non-standard procedure)... 123 4.3.2.1 In-life observations... 123 4.3.2.1.1 Behavior... 123 4.3.2.1.2 Body weight... 123 4.3.2.1.3 Rectal temperature... 124 4.3.2.1.4 Organ weight... 125 4.3.2.2 Hematological parameters... 125 4.3.2.3 Parasitological responses... 127 4.3.2.3.1 Effect of rdim-1bm on L3 induced infection... 127 4.3.2.4 Immunological responses... 128 4.3.2.4.1 Effect on humoral responses: IgG and its subclass, IgE, IgM and IgA...128 4.3.2.5 Effect on cell mediated immune responses... 129 4.3.2.5.1 Lymphocyte transformation test (LTT)... 129 4.3.2.5.2 Macrophage phagocytic activity test (MAT)... 130 4.3.2.5.3 NO release... 130 4.3.2.5.4 Cytokine release... 130 4.3.3 6- Week immunization schedule (non-standard procedure)... 134 4.3.3.1 In-life observations... 134 4.3.3.1.1 Behavior... 134 4.3.3.1.2 Body weight... 134 4.3.3.1.3 Rectal temperature... 135 4.3.3.1.4 Organ weight... 136 4.3.3.2 Hematological parameters... 136 4.3.3.3 Parasitological responses... 138 4.3.3.3.1 Effect of rdim-1bm on L3 induced infection... 138 4.3.3.4 Immunological responses... 139

4.3.3.4.1 Effect on humoral responses: IgG and its subclass, IgE, IgM and IgA... 139 4.3.3.5 Effect on cell mediated responses... 140 4.3.3.5.1 Lymphocyte transformation test (LTT)... 141 4.3.3.5.2 Macrophage phagocytic activity test (MAT)... 141 4.3.3.5.3 NO release... 141 4.3.3.5.4 Cytokine release... 142 4.3.4 Histopathological studies...144 CHAPTER-5... 145 5 DISCUSSION... 145 CHAPTER-6... 155 6 SUMMARY... 155 CHAPTER-7... 162 7 BIBLIOGRAPHY... 162 LIST OF PUBLICATIONS...195